[Leish-l] RES: testing vaccinated dogs for immunopotentiation
Patrick Bastien
patrick.bastien at univ-montp1.fr
Fri Oct 7 14:30:42 BRT 2011
There were several earlier reports of this vertical transmission, even
in the US: among others,
Rosypal AC, J.Parasitol. 2005, 970-972 and 113-115
Magno da Silva, Vet Parasitol 2009
Pangrazio, Vet Parasitol 2009
Best regards
P. Bastien
Professeur Patrick Bastien
Laboratoire de Parasitologie-Mycologie, Faculté de Médecine
UMR MIVEGEC (CNRS 5290 - IRD 224 - Université Montpellier 1)
Centre National de Référence des Leishmania
CHU de Montpellier
39 Avenue Charles Flahault
34295 Montpellier Cedex 5, France
"Chang, Kwang-Poo" <KwangPoo.Chang at rosalindfranklin.edu> a écrit :
> What Jenni said indicates that transplacental transmission of canine
> leishmaniasis has some implication in considering dog vaccination.
>
>
>
> Of further interest is the question of whether this transplacental
> transmission could also occur in other reservoir animals or even in
> human leishmaniasis ? I recall the description of such transmission in
> human cases in some very early literature, but that has been always
> considered as unlikely or extremely rare, more as a hypothesis than
> reality. This issue may have been addressed in more recent
> epidemiological studies of VL familial clustering in well-established
> endemic sites ? Congenital transmission might escape our attention,
> should the outcome be largely asymptomatic ?
>
>
>
> KP
>
>
>
> ________________________________
>
> From: Jennie Blackwell [mailto:jmb37 at cam.ac.uk]
> Sent: Wednesday, October 05, 2011 6:46 PM
> To: Chang, Kwang-Poo
> Cc: Petersen, Christine A [V PTH]; TECSA - Luiz Ristow; John David;
> leish-l at lineu.icb.usp.br
> Subject: Re: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
>
>
> I doubt it. Treatment might but if the mum was already infected and
> passed the parasite to the foetus I don't see how a vaccine would work
> to clear the parasite from the foetus!
>
>
>
> Slightly different question as to whether vaccinating mums will give
> them sufficient protection to not pass the parasite to the pup in utero
> should they get infected themselves after vaccination.
>
>
>
> Cheers all, Jennie
>
> Jenefer M. Blackwell
>
> TICHR, CCHR, UWA
>
> Phone: +61 8 94897910
>
> From my iPhone
>
>
> On 29 Sep 2011, at 00:36, "Chang, Kwang-Poo"
> <KwangPoo.Chang at rosalindfranklin.edu> wrote:
>
> Of interest is the question of whether vaccination would clear
> the infection of the pub, which has congenitally inherited L infantum ?
>
>
>
> KP
>
>
>
>
> ________________________________
>
>
> From: Petersen, Christine A [V PTH] [mailto:kalicat at iastate.edu]
>
> Sent: Wednesday, September 28, 2011 11:23 AM
> To: Chang, Kwang-Poo; TECSA - Luiz Ristow; John David
> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
>
>
> The reference for this article is:
> <http://www.ncbi.nlm.nih.gov/pubmed/21532741>
> http://www.ncbi.nlm.nih.gov/pubmed/21532741
>
> As it was published in a PLoS journal its free access to all.
>
> Based on our studies and recent ones from Brazil, I do believe
> that to remove Leish from the canine reservoir, transmission from mom to
> pup will need to be addressed.
>
> Christy Petersen
>
>
>
> From: Chang, Kwang-Poo
> [mailto:KwangPoo.Chang at rosalindfranklin.edu]
> Sent: Wednesday, September 28, 2011 10:20 AM
> To: TECSA - Luiz Ristow; John David
> Cc: leish-l at lineu.icb.usp.br; Petersen, Christine A [V PTH]
> Subject: RE: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
>
>
> Christine Petersen published an article about transplacental
> transmission of L infantum in the USA canine leishmaniasis. I just
> wonder about the implication of this finding in considering vaccination
> against the disease transmitted this way ?
>
>
>
> KP
>
>
>
>
> ________________________________
>
>
> From: <mailto:leish-l-bounces at lineu.icb.usp.br>
> leish-l-bounces at lineu.icb.usp.br
> [mailto:leish-l-bounces at lineu.icb.usp.br]
> <mailto:%5bmailto:leish-l-bounces at lineu.icb.usp.br%5d> On Behalf Of
> TECSA - Luiz Ristow
> Sent: Wednesday, September 28, 2011 9:08 AM
> To: 'John David'
> Cc: <mailto:leish-l at lineu.icb.usp.br> leish-l at lineu.icb.usp.br
> Subject: [Leish-l] RES: testing vaccinated dogs for
> immunopotentiation
>
>
>
> Hi !
>
>
>
> There are these papers about
>
> These need a very critical reading to discuss
>
> This discussion with all about the matter and these papers is
> very welcome! (at least for me!)
>
> Regards for all
>
> Luiz Ristow
>
>
>
> <image001.gif>
>
>
>
> De: <mailto:leish-l-bounces at lineu.icb.usp.br>
> leish-l-bounces at lineu.icb.usp.br
> [mailto:leish-l-bounces at lineu.icb.usp.br]
> <mailto:%5bmailto:leish-l-bounces at lineu.icb.usp.br%5d> Em nome de John
> David
> Enviada em: segunda-feira, 26 de setembro de 2011 18:44
> Para: Dr GR Rajasekariah
> Cc: <mailto:leish-l at lineu.icb.usp.br> leish-l at lineu.icb.usp.br;
> Carlos Gouvea; hubert mazure; <mailto:smithyman at cellabs.com.au>
> smithyman at cellabs.com.au
> Assunto: Re: [Leish-l] testing vaccinated dogs for
> immunopotentiation
>
>
>
> I think that for any vaccine developed to protect dogs against
> VL, but which is also meant to prevent transmission of VL to humans, the
> developers should show that after the vaccinated dog has been challenged
> with Leishmania, it does not transmit Leishmania to sand flies.
>
> John R David, M.D.
>
> Richard Pearson Strong Professor Emeritus
>
> Department of Immunology and Infectious Diseases
>
> Harvard School of Public Health
>
> Professor of Medicine, Harvard Medical School
>
> 300 W. 23rd Street, Apt. 13K
>
> New York, NY, 10011
>
> Tel: 212 414 8646
>
> Email: <mailto:jdavid at hsph.harvard.edu> jdavid at hsph.harvard.edu
>
>
>
>
>
> On Sep 19, 2011, at 12:04 AM, Dr GR Rajasekariah wrote:
>
>
>
> Hello EveryOne,
> I am responding to the topic on European VL Dog vaccine.
> It is a great challenge in devising a protective vaccine
> against visceral leishmaniasis in dogs. This point equally applies the
> same challenge for human situation.
> Because Th-2 response is so dominant during VL infection,
> modulating Th-2 into Th-1 response is a big challenge to immunologists.
>
> Key points lies in the presentation of appropriate antigen in
> appropriate dose to stimulate the Th-1 dependent protective immune
> response.
> I understand several vaccines are in the market and real
> efficacy of these vaccines will come out once introduced to field
> conditions.
>
> I just wanted to inform you that we have a suitable antibody kit
> for testing the immunopotentiation in dogs following vaccination of
> dogs.
> Our assay is based on the released promastigote antigens.
> It is a highly sensitive assay.
> Currently we supply reagents for determination of total IgG
> antibodies in serum.
> If any particular group is interested then we are able to
> provide appropriate reagent for detection of specific IgG2 and other
> isotype specific antibody detection.
> Because our antibody detection ELISA is based on the
> exo-antigens such an ELISA would be of exceptional type for measuring
> antibody response in vaccinated animals.
> Highly suitable for diagnosing dogs responded to vaccines.
>
> Recently I came to know that some of commercial kits were found
> to be not useful for detecting seroconversion in dogs vaccinated with
> FML vaccine (Leish-Immune) in Brazil.
> Because we use released antigens in our kit, any such problems
> will overcome if they use Canine Leish IgG CELISA (Manufacturer Cellabs
> Pty Ltd Brookvale NSW Australia email <mailto:sales at cellabs.com.au>
> sales at cellabs.com.au).
> If any one is interested to know more about our antibody
> detection ELISA based on exo-antigens please contact us.
>
> This is for your kind information.
>
> Dr GR Rajasekariah
> Sydney
> Australia
> <mailto:raj at cellabs.com.au> raj at cellabs.com.au
>
>
>
>
>
>
> ----- Original Message ----- From: <
> <mailto:leish-l-request at lineu.icb.usp.br>
> leish-l-request at lineu.icb.usp.br>
> To: < <mailto:leish-l at lineu.icb.usp.br>
> leish-l at lineu.icb.usp.br>
> Sent: Wednesday, August 10, 2011 5:18 PM
> Subject: Leish-l Digest, Vol 44, Issue 3
>
> Send Leish-l mailing list submissions to
>
> <mailto:leish-l at lineu.icb.usp.br>
> leish-l at lineu.icb.usp.br
>
>
>
> To subscribe or unsubscribe via the World Wide Web,
> visit
>
>
> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
> or, via email, send a message with subject or body
> 'help' to
>
> <mailto:leish-l-request at lineu.icb.usp.br>
> leish-l-request at lineu.icb.usp.br
>
>
>
> You can reach the person managing the list at
>
> <mailto:leish-l-owner at lineu.icb.usp.br>
> leish-l-owner at lineu.icb.usp.br
>
>
>
> When replying, please edit your Subject line so it is
> more specific
>
> than "Re: Contents of Leish-l digest..."
>
>
>
>
>
> Today's Topics:
>
>
>
> 1. European VL Dog Vaccine - CaniLeish?: (jeffrey shaw)
>
> 2. Re: FW: Leishmaniasis Pathology Network (Moazzem
> Hossain)
>
> 3. Re: FW: Leishmaniasis Pathology Network (Moazzem
> Hossain)
>
>
>
>
>
>
> ----------------------------------------------------------------------
>
>
>
> Message: 1
>
> Date: Tue, 9 Aug 2011 15:18:44 +0000
>
> From: jeffrey shaw < <mailto:jayusp at hotmail.com>
> jayusp at hotmail.com>
>
> Subject: [Leish-l] European VL Dog Vaccine - CaniLeish?:
>
> To: Leish-L < <mailto:leish-l at lineu.icb.usp.br>
> leish-l at lineu.icb.usp.br>
>
> Message-ID: <
> <mailto:COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
> COL101-W1CDD4171D44B715B795E9CB200 at phx.gbl>
>
> Content-Type: text/plain; charset="windows-1252"
>
>
>
>
>
> CaniLeish?:
>
> The European Commission granted a marketing
> authorisation valid throughout the European Union, for CaniLeish to
> Virbac S.A. on 14/03/2011.
>
> This vaccine, CaniLeish?, will initially be launched in
> Portugal at the end of the first half of 2011. This will be followed
> rapidly by launches in other countries in the endemic area: Spain,
> France, Greece and Italy (not in chronological order). This roll-out
> takes account of the geographical prevalence of the disease and the time
> required to build vaccine production up to full capacity. The launch in
> Northern European countries from where there is a flow of summer
> visitors to the endemic area will be part of a second phase.
>
> The basis of this vaccine are excreted proteins plus a
> saponin adjuvant purified from Quil-A. Its efficacy was determined in a
> 2 year open field trial.
>
> The vaccine is given to dogs as three injections,
> three weeks apart, under the skin. The first injection can be given from
> six months of age, the second injection is given three weeks later and
> the third three weeks from the second one. Afterward a single ?booster?
> should be given every year to maintain protection.
>
> -------------- next part --------------
>
> An HTML attachment was scrubbed...
>
> URL: <
> <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e
> /attachment-0001.htm>
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110809/f2404f5e/
> attachment-0001.htm>
>
>
>
> ------------------------------
>
>
>
> Message: 2
>
> Date: Wed, 10 Aug 2011 13:07:17 +0600
>
> From: Moazzem Hossain < <mailto:directordcbd at gmail.com>
> directordcbd at gmail.com>
>
> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
> Network
>
> To: jeffrey shaw < <mailto:jayusp at hotmail.com>
> jayusp at hotmail.com>, "Prof. Paul Kaye"
>
> < <mailto:paul.kaye at york.ac.uk> paul.kaye at york.ac.uk>
>
> Cc: "Prof. Dr. Moazzem Hossain" <
> <mailto:profdrmoazzemhossain at gmail.com> profdrmoazzemhossain at gmail.com>,
>
> Leish-L < <mailto:leish-l at lineu.icb.usp.br>
> leish-l at lineu.icb.usp.br>
>
> Message-ID:
>
> <
> <mailto:CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.c
> om> CAE-TCmS=i=WaT8cAeOXUJmot=KPvMQSLKar6CTfuUBK9M9tsUw at mail.gmail.com>
>
> Content-Type: text/plain; charset=windows-1252
>
>
>
> 10 Aug 2011
>
>
>
> Dear Professor Paul Kaye,
>
>
>
> Thank you for your email. Please find attached our
> supportive letter
>
> of interest for Leishmaniasis Pathology Network.
>
> Looking forward for your kind response.
>
>
>
> Best regards.
>
>
>
>
>
> --
>
> *Prof. Dr. Moazzem Hossain *
>
> Ex - Director Disease Control
>
> Ministry of Health & Family Welfare
>
> Government of Bangladesh
>
> *Mailing address*:
>
> Founder Chairman and Project Director
>
> Institute of Allergy & Clinical Immunology of Bangladesh
> (IACIB)
>
> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
>
> Dhaka -1205, Bangladesh.
>
> Phone:880-2-8115646 (O )
>
> 880-1715038551(Mobile)
>
> Email: <mailto:directordcbd at gmail.com>
> directordcbd at gmail.com
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> On 8/9/11, jeffrey shaw < <mailto:jayusp at hotmail.com>
> jayusp at hotmail.com> wrote:
>
>
>
>
>
>
>
> Date: Tue, 9 Aug 2011 11:58:52 +0100
>
> From: <mailto:paul.kaye at york.ac.uk>
> paul.kaye at york.ac.uk
>
>
>
> Subject: Leishmaniasis Pathology Network
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> Dear all,
>
> Invitation to participate in a global
> pathology
>
> network for
>
> research and training in leishmaniasis
> (LeishPathNet)
>
> You may recall the Dormy House meeting in
> 2008
>
> and some of
>
> the plans we put forward? Over
>
> the past
>
> couple years, I have also spoken more to a
> few of you about one
>
> idea that was
>
> formulated at Dormy, namely of setting up a
> digital pathology
>
> network. I have
>
> also had numerous discussions with the
> major equipment
>
> manufacturers to see if
>
> any of them would be supportive of helping
> us to develop such an
>
> initiative. There have
>
> been two major
>
> develoments recently. First,
>
> Carl Zeiss
>
> is willing to work with us to set up an
> integrated global digital
>
> pathology
>
> network (providing a significant financial
> and technical
>
> contribution) and
>
> second, the Wellcome Trust is willing to
> review a pre-proposal to
>
> fund the
>
> initiative through their new Biomedical
> Resources Grant scheme
>
> (
> <http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
> rategic-awards-and-initiatives/wtdv031727.htm>
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Str
> ategic-awards-and-initiatives/wtdv031727.htm)
>
> .
>
> I have attached an outline of the project
> that
>
> I had sent to
>
> the Trust for their initial views, which I
> think is reasonably
>
> self-explanatory.
>
> They appeared very
>
> enthusiastic! The main
>
> question now is whether enough of
>
> you are still supportive? [ I will also be
> sending this email to
>
> others, but please feel free to circulate ]
>
>
>
>
>
> I think the
>
> project will be
>
> challenging, but success could have a
> real impact on the way we
>
> conduct
>
> business. It should serve not only as a
> vehicle to enhance
>
> research in
>
> leishmaniasis, but the model would be
> equally applicable across
>
> a broad range
>
> of diseases and global challenges (with
> leishmaniasis setting
>
> the pace).
>
> If we wish to
>
> proceed, the requirements
>
> are that we submit a pre-proposal to the
> Trust by Oct 18th 2011.
>
> This pre-proposal is short (4 sections of
> 350 words) and
>
> requires
>
> letters of support from the community.
>
> If you are
>
> supportive of the idea that
>
> we try to take this forward (and there is
> plenty of scope for
>
> later iteration
>
> of the detail), I would be grateful if
> you could please provide
>
> me with a
>
> letter of support by September
>
> 12th
>
> 2011, indicating whether you would like
> to be a network
>
> partner if the bid
>
> is successful. You could
>
> also be
>
> supportive but not wish to become
> directly involved at this
>
> stage, and such
>
> letters are equally valuable. Your letter
> might also stress the
>
> added value
>
> that the network could provide, its
> importance for research and
>
> training and/or
>
> for progressing the translational agenda.
>
> It would also be an opportunity to
> indicate whether your
>
> group (or
>
> institute, if multiple groups) would be
> interested in bidding to
>
> be one of the
>
> initial ?designated laboratories?.
>
> If there is
>
> sufficient support to
>
> proceed and if subsequently the
> pre-proposal is successful (we
>
> will know on 22nd
>
> Nov), then I will need a few volunteers
> to help finalise the
>
> full proposal,
>
> which will be due on Jan 26th 2012.
>
> A funding decision will be made on May
> 26th
>
> 2012.
>
> Best wishes
>
> and of course I am happy to
>
> discuss any points further (though I will
> be out of the UK from
>
> Aug 10 ?Sept
>
> 12)
>
> Paul
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> --
>
> Professor Paul Kaye, Ph.D., FRCPath.
>
> Deputy Dean (Research), Hull York Medical
> School, and
>
> Director, Centre for Immunology and Infection
>
> Department of Biology and Hull York Medical
> School
>
> University of York
>
> Wentworth Way
>
> York YO10 5YW
>
> United Kingdom
>
>
>
> Tel: +44 (0)1904 328840
>
> Fax: +44 (0)1904 328844
>
> Email: <mailto:paul.kaye at york.ac.uk>
> paul.kaye at york.ac.uk < <mailto:paul.kaye at york.ac.uk>
> mailto:paul.kaye at york.ac.uk>
>
>
>
> Centre Administrator and PA: Elizabeth Greensted
>
> Tel: 01904 328845
>
> Email: <mailto:liz.greensted at york.ac.uk>
> liz.greensted at york.ac.uk < <mailto:liz.greensted at york.ac.uk>
> mailto:liz.greensted at york.ac.uk>
>
>
>
> Centre Email: <mailto:cii at york.ac.uk>
> cii at york.ac.uk < <mailto:cii at york.ac.uk> mailto:cii at york.ac.uk>
>
>
>
> Centre website: <http://www.york.ac.uk/cii>
> http://www.york.ac.uk/cii
>
>
>
> Times Higher Education University of the Year
> 2010
>
>
>
> Email disclaimer:
> <http://www.york.ac.uk/docs/disclaimer/email.htm>
> http://www.york.ac.uk/docs/disclaimer/email.htm
>
>
>
>
>
>
>
>
>
> ------------------------------
>
>
>
> Message: 3
>
> Date: Wed, 10 Aug 2011 13:06:47 +0600
>
> From: Moazzem Hossain < <mailto:directordcbd at gmail.com>
> directordcbd at gmail.com>
>
> Subject: Re: [Leish-l] FW: Leishmaniasis Pathology
> Network
>
> To: jeffrey shaw < <mailto:jayusp at hotmail.com>
> jayusp at hotmail.com>, "Prof. Paul Kaye"
>
> < <mailto:paul.kaye at york.ac.uk> paul.kaye at york.ac.uk>
>
> Cc: "Prof. Dr. Moazzem Hossain" <
> <mailto:profdrmoazzemhossain at gmail.com> profdrmoazzemhossain at gmail.com>,
>
> Leish-L < <mailto:leish-l at lineu.icb.usp.br>
> leish-l at lineu.icb.usp.br>
>
> Message-ID:
>
> <
> <mailto:CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.c
> om> CAE-TCmQNUkZdNE5w+Z20bjLC-=vvV9BCP6OLOm9f6RV-BfpXvA at mail.gmail.com>
>
> Content-Type: text/plain; charset="windows-1252"
>
>
>
> 10 Aug 2011
>
>
>
> Dear Professor Paul Kaye,
>
>
>
> Thank you for your email. Please find attached our
> supportive letter
>
> of interest for Leishmaniasis Pathology Network.
>
> Looking forward for your kind response.
>
>
>
> Best regards.
>
>
>
>
>
> --
>
> *Prof. Dr. Moazzem Hossain *
>
> Ex - Director Disease Control
>
> Ministry of Health & Family Welfare
>
> Government of Bangladesh
>
> *Mailing address*:
>
> Founder Chairman and Project Director
>
> Institute of Allergy & Clinical Immunology of Bangladesh
> (IACIB)
>
> Room 4 - 5 (2nd Floor), Green Super Market, Green Road
>
> Dhaka -1205, Bangladesh.
>
> Phone:880-2-8115646 (O )
>
> 880-1715038551(Mobile)
>
> Email: <mailto:directordcbd at gmail.com>
> directordcbd at gmail.com
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> On 8/9/11, jeffrey shaw < <mailto:jayusp at hotmail.com>
> jayusp at hotmail.com> wrote:
>
>
>
>
>
>
>
> Date: Tue, 9 Aug 2011 11:58:52 +0100
>
> From: <mailto:paul.kaye at york.ac.uk>
> paul.kaye at york.ac.uk
>
>
>
> Subject: Leishmaniasis Pathology Network
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> Dear all,
>
> Invitation to participate in a global
> pathology
>
> network for
>
> research and training in leishmaniasis
> (LeishPathNet)
>
> You may recall the Dormy House meeting in
> 2008
>
> and some of
>
> the plans we put forward? Over
>
> the past
>
> couple years, I have also spoken more to a
> few of you about one
>
> idea that was
>
> formulated at Dormy, namely of setting up a
> digital pathology
>
> network. I have
>
> also had numerous discussions with the
> major equipment
>
> manufacturers to see if
>
> any of them would be supportive of helping
> us to develop such an
>
> initiative. There have
>
> been two major
>
> develoments recently. First,
>
> Carl Zeiss
>
> is willing to work with us to set up an
> integrated global digital
>
> pathology
>
> network (providing a significant financial
> and technical
>
> contribution) and
>
> second, the Wellcome Trust is willing to
> review a pre-proposal to
>
> fund the
>
> initiative through their new Biomedical
> Resources Grant scheme
>
> (
> <http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/St
> rategic-awards-and-initiatives/wtdv031727.htm>
> http://www.wellcome.ac.uk/Funding/Biomedical-science/Funding-schemes/Str
> ategic-awards-and-initiatives/wtdv031727.htm)
>
> .
>
> I have attached an outline of the project
> that
>
> I had sent to
>
> the Trust for their initial views, which I
> think is reasonably
>
> self-explanatory.
>
> They appeared very
>
> enthusiastic! The main
>
> question now is whether enough of
>
> you are still supportive? [ I will also be
> sending this email to
>
> others, but please feel free to circulate ]
>
>
>
>
>
> I think the
>
> project will be
>
> challenging, but success could have a
> real impact on the way we
>
> conduct
>
> business. It should serve not only as a
> vehicle to enhance
>
> research in
>
> leishmaniasis, but the model would be
> equally applicable across
>
> a broad range
>
> of diseases and global challenges (with
> leishmaniasis setting
>
> the pace).
>
> If we wish to
>
> proceed, the requirements
>
> are that we submit a pre-proposal to the
> Trust by Oct 18th 2011.
>
> This pre-proposal is short (4 sections of
> 350 words) and
>
> requires
>
> letters of support from the community.
>
> If you are
>
> supportive of the idea that
>
> we try to take this forward (and there is
> plenty of scope for
>
> later iteration
>
> of the detail), I would be grateful if
> you could please provide
>
> me with a
>
> letter of support by September
>
> 12th
>
> 2011, indicating whether you would like
> to be a network
>
> partner if the bid
>
> is successful. You could
>
> also be
>
> supportive but not wish to become
> directly involved at this
>
> stage, and such
>
> letters are equally valuable. Your letter
> might also stress the
>
> added value
>
> that the network could provide, its
> importance for research and
>
> training and/or
>
> for progressing the translational agenda.
>
> It would also be an opportunity to
> indicate whether your
>
> group (or
>
> institute, if multiple groups) would be
> interested in bidding to
>
> be one of the
>
> initial ?designated laboratories?.
>
> If there is
>
> sufficient support to
>
> proceed and if subsequently the
> pre-proposal is successful (we
>
> will know on 22nd
>
> Nov), then I will need a few volunteers
> to help finalise the
>
> full proposal,
>
> which will be due on Jan 26th 2012.
>
> A funding decision will be made on May
> 26th
>
> 2012.
>
> Best wishes
>
> and of course I am happy to
>
> discuss any points further (though I will
> be out of the UK from
>
> Aug 10 ?Sept
>
> 12)
>
> Paul
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
> --
>
> Professor Paul Kaye, Ph.D., FRCPath.
>
> Deputy Dean (Research), Hull York Medical
> School, and
>
> Director, Centre for Immunology and Infection
>
> Department of Biology and Hull York Medical
> School
>
> University of York
>
> Wentworth Way
>
> York YO10 5YW
>
> United Kingdom
>
>
>
> Tel: +44 (0)1904 328840
>
> Fax: +44 (0)1904 328844
>
> Email: <mailto:paul.kaye at york.ac.uk>
> paul.kaye at york.ac.uk < <mailto:paul.kaye at york.ac.uk>
> mailto:paul.kaye at york.ac.uk>
>
>
>
> Centre Administrator and PA: Elizabeth Greensted
>
> Tel: 01904 328845
>
> Email: <mailto:liz.greensted at york.ac.uk>
> liz.greensted at york.ac.uk < <mailto:liz.greensted at york.ac.uk>
> mailto:liz.greensted at york.ac.uk>
>
>
>
> Centre Email: <mailto:cii at york.ac.uk>
> cii at york.ac.uk < <mailto:cii at york.ac.uk> mailto:cii at york.ac.uk>
>
>
>
> Centre website: <http://www.york.ac.uk/cii>
> http://www.york.ac.uk/cii
>
>
>
> Times Higher Education University of the Year
> 2010
>
>
>
> Email disclaimer:
> <http://www.york.ac.uk/docs/disclaimer/email.htm>
> http://www.york.ac.uk/docs/disclaimer/email.htm
>
>
>
>
>
> -------------- next part --------------
>
> A non-text attachment was scrubbed...
>
> Name: Letter Leish UK.doc
>
> Type: application/msword
>
> Size: 46080 bytes
>
> Desc: not available
>
> URL: <
> <http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a
> /attachment.doc>
> http://lineu.icb.usp.br/pipermail/leish-l/attachments/20110810/73f2ae6a/
> attachment.doc>
>
>
>
> ------------------------------
>
>
>
> _______________________________________________
>
> Leish-l mailing list
>
> <mailto:Leish-l at lineu.icb.usp.br>
> Leish-l at lineu.icb.usp.br
>
>
> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
>
>
>
> End of Leish-l Digest, Vol 44, Issue 3
>
> **************************************
>
>
>
>
>
>
> =======
> Email scanned by PC Tools - No viruses or spyware found.
> (Email Guard: 7.0.0.26, Virus/Spyware Database: 6.18330)
> <http://www.pctools.com/> http://www.pctools.com/
> =======
> _______________________________________________
> Leish-l mailing list
> <mailto:Leish-l at lineu.icb.usp.br> Leish-l at lineu.icb.usp.br
> <http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l>
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
>
>
>
> _______________________________________________
> Leish-l mailing list
> Leish-l at lineu.icb.usp.br
> http://lineu.icb.usp.br/cgi-bin/mailman/listinfo/leish-l
>
>
More information about the Leish-l
mailing list